Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NYSE:MRK

Merck & Co., Inc. Q3 2026 Earnings Date & Estimates

Merck & Co., Inc. logo
$144.76 -2.48 (-1.69%)
As of 12:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. The conference call is scheduled for 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Merck & Co., Inc. in Q3 2026

Merck & Co., Inc. is expected to post earnings of $2.09 per share on revenue of $17.31 billion. In the same quarter a year earlier Merck & Co., Inc. reported $2.58 per share on revenue of $17.28 billion. Merck & Co., Inc. last reported on August 4, 2026, posting -$0.13 per share and beating the -$0.26 consensus estimate. Merck & Co., Inc. has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$2.09
Expected Revenue
$17.31 billion
Prior-Year EPS
$2.58
Prior-Year Revenue
$17.28 billion
Expected EPS Growth
-19.0%
Expected Revenue Growth
+0.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.13 (Beat by +$0.13)
Last Quarter Revenue
$16.61 billion
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Merck & Co., Inc. Q3 2026 Earnings FAQ

Merck & Co., Inc. (NYSE:MRK) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Merck & Co., Inc.'s Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Merck & Co., Inc. to post earnings of $2.09 per share for Q3 2026.

The consensus revenue estimate for Merck & Co., Inc. is $17.31 billion for Q3 2026.

Merck & Co., Inc. Earnings Headlines

Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
 |  cnbc.comhttps://www.cnbc.com/2026/10/23/moderna-merck-cancer-vaccine-data.html
Merck: A 71% Rally Leaves Little Margin Of Safety Ahead Of Keytruda's Patent Cliff
 |  seekingalpha.comhttps://seekingalpha.com/article/4956908-merck-a-71-percent-rally-leaves-little-margin-of-safety-ahead-of-keytrudas-patent-cliff
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
October 23 at 1:00 AM  |  InvestorPlace (Ad)
Moderna stock extends decline after leaked data on melanoma vaccine trial
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/article/moderna-stock-extends-decline-after-leaked-data-on-melanoma-vaccine-trial-134927914.html
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
 |  247wallst.comhttps://247wallst.com/investing/2026/10/23/moderna-sinks-4-after-18-plunge-as-melanoma-vaccine-selloff-extends-merck-and-pfizer-slip/?utm_source=snapi
Merck (MRK) Wins EU Approval For KEYTRUDA Plus Padcev In Bladder Cancer
October 22 at 11:01 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-mrk-wins-eu-approval-221054950.html
See More Merck & Co., Inc. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck & Co., Inc.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck & Co., Inc. and other key companies, straight to your email.

About Merck & Co., Inc.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes. Its portfolio also includes products such as Bridion, which reverses certain effects of muscle-relaxing medicines used during surgery. Through Merck Animal Health, the company provides vaccines, pharmaceutical products and technology-enabled solutions for livestock, companion animals and aquaculture.

The company traces its roots to the U.S. operations established by the Merck family in 1891 and operates independently from Germany-based Merck KGaA, which uses the name EMD in the United States and Canada. Merck & Co. has research, manufacturing and commercial operations across North America, Europe, Asia-Pacific, Latin America, Africa and other international markets. Robert M. Davis serves as the company’s chairman and chief executive officer.

View Merck & Co., Inc. Profile
Earnings Tools